

# Tarah J Ballinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5648779/publications.pdf>

Version: 2024-02-01

25  
papers

974  
citations

840776

11  
h-index

677142

22  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1859  
citing authors

#	ARTICLE	IF	CITATIONS
1	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	1.6	23
2	Abstract PD9-10: BRE12-158: A post-neoadjuvant, randomized phase 2 trial of personalized therapy vs. treatment of physician's choice for patients with residual triple negative breast cancer. <i>Cancer Research</i> , 2022, 82, PD9-10-PD9-10.	0.9	0
3	Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). <i>Cancer</i> , 2022, 128, 2174-2181.	4.1	5
4	Reply to K. Nozawa et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200288.	1.6	0
5	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3235-3241.	7.0	6
6	Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158. <i>Clinical Cancer Research</i> , 2021, 27, 1195-1199.	7.0	5
7	A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 626180.	2.8	7
8	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	2.2	4
9	Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2021, 9, e3741.	0.6	4
10	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. <i>Clinical Cancer Research</i> , 2021, 27, 5810-5817.	7.0	19
11	Patient-reported outcomes in the Translational Breast Cancer Research Consortium. <i>Cancer</i> , 2020, 126, 922-930.	4.1	4
12	Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. <i>Contemporary Clinical Trials</i> , 2020, 98, 106168.	1.8	1
13	Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 161-167.	1.0	1
14	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	1.6	276
15	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	7.1	161
16	Cancer-Associated Muscle Dysfunction. , 2020, , 379-389.		0
17	Impact of primary breast cancer therapy on energetic capacity and body composition. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 445-452.	2.5	16
18	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 308.	2.8	62

#	ARTICLE	IF	CITATIONS
19	Discerning the clinical relevance of biomarkers in early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 89-97.	2.5	9
20	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	7.0	19
21	Triple Negative Breast Cancer—Review of Current and Emerging Therapeutic Strategies. <i>Oncology &amp; Hematology Review</i> , 2016, 12, 89.	0.2	3
22	How we manage <sc>JAK</sc> inhibition in allogeneic transplantation for myelofibrosis. <i>European Journal of Haematology</i> , 2015, 94, 115-119.	2.2	14
23	Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. <i>Clinical Breast Cancer</i> , 2015, 15, 171-180.	2.4	35
24	Subtyping of triple-negative breast cancer: Implications for therapy. <i>Cancer</i> , 2015, 121, 8-16.	4.1	280
25	Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 389-399.	2.5	20